Devazepide[1] (L-364,718, MK-329) is benzodiazepine drug, but with quite different actions from most benzodiazepines, lacking affinity for GABAA receptors and instead acting as an CCKA receptor antagonist.[2] It increases appetite and accelerates gastric emptying,[3][4] and has been suggested as a potential treatment for a variety of gastrointestinal problems including dyspepsia, gastroparesis and gastric reflux.[5] It is also widely used in scientific research into the CCKA receptor.[6][7]
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
IUPHAR/BPS |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
ECHA InfoCard | 100.208.547 |
Chemical and physical data | |
Formula | C25H20N4O2 |
Molar mass | 408.461 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(what is this?) (verify) |
Devazepide is synthesised in a similar manner to other benzodiazepines.[8][9]